Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.60    3.80 (2.49%)
Bid:
156.40
Ask:
156.80
Spread: 0.40 (0.256%)
Market Cap: £896.25m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

First quarter trading update

30 Apr 2024 07:00

RNS Number : 4859M
Elementis PLC
30 April 2024
 

 

30 April 2024

 

Elementis plc

First quarter trading update

Sales and profit growth with margin improvement; CMD objectives on track.

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues its scheduled trading update for the three months ("the quarter") ended 31 March 2024.

Elementis will publish its interim results for the six months to 30 June 2024 on 1 August 2024.

 

Business performance

The Group delivered a good first quarter performance, with constant currency revenue up by 3%, adjusted operating profit up by double digits, and a material improvement in operating margin, compared to Q1 2023.

Personal Care sales in the quarter were broadly flat on the strong prior year period. We saw good growth in Cosmetics, offset by an expected slower start to the year in AP Actives due to order phasing.

Performance Specialties delivered an improved performance in the quarter, with sales and profit above a weak prior year period.

· Coatings sales increased low double-digit percentage versus the prior year period, benefiting from volume restocking and improved mix.

· Talc had a challenging quarter, impacted by the Finnish transport workers' union strike in early March, closing ports and stopping railway freight traffic for four weeks. This resulted in higher logistics costs and reduced sales in the quarter.

Cash generation in the first quarter was in line with expectations, with further reduction in inventory levels.

 

Outlook

The year has started well. Whilst we have not yet seen a positive step change in the demand environment, we remain confident about our ability to deliver profit growth and margin improvement in line with expectations1.

Implementation of the growth and efficiency programmes presented at the November 2023 Capital Markets Day ("CMD") is progressing well. Self help is critical in this, particularly the $30 million of cost savings commitment, and we are on-track to deliver $12 million this year and $18 million in 2025. In addition, we launched five new products and delivered $13 million of sales from new business in the first quarter, despite a continued challenging demand environment.

 

Paul Waterman, CEO of Elementis, said:

"Elementis has had a good start to the 2024 financial year, with our focus firmly on the execution of our CMD objectives. I am confident that our clear strategy focused on innovation, growth and efficiency will allow us to achieve a significant improvement in our full-year performance and continued margin expansion, in line with expectations1."

Note: 1. Based on company compiled consensus dated 25 April 2024, adjusted operating profit of $117 million and adjusted operating margin of 15.8% for the financial year 2024.

 

Enquiries

Investors: Eva Hatfield, Elementis plc Tel: +44 7553 340380

Press: Martin Robinson/Olivia Peters, Teneo Tel: +44 (0) 20 7353 4200

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKCBKOBKDQQB
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.